

Original Research Article

Etiology of Antibiotic Associated Diarrhea with Special Reference to *Clostridium difficile*

ABSTRACT

Introduction: Antibiotic associated diarrhea (AAD) is a common side effect of treatment with antibiotic. Depending on the antibiotic used, up to 25% of patients experience such unpleasant bowel conditions. The normal flora is replaced by pathogenic organisms like *Candida spp.*, *Clostridium difficile* etc which play an important role in the causation AAD. Almost all the antibiotics have been associated with diarrhea. *C.difficile* is known to occur as an outbreak in health care settings in cases of AAD. However reports from India are in-frequent. So the present study was undertaken to asses the role of different pathogen in causation of AAD and to evaluate the role of various antimicrobials in causation of AAD.

Study design: Prospective observational study.

Place and Duration of Study: Department of Microbiology B.J. Government Medical College and Sassoon General Hospital, Pune over the period of two years.

Material and Method: Stool samples of 70 patients developing AAD were included in the study. Samples were subjected for aerobic, anaerobic and fungal culture. *C.difficile* toxin was detected in stool by ELISA. PCR was also performed to look for the presence of *C.difficile* DNA in stool sample.

Results: Majority of the patients was from the age group 31 to 40 years with female preponderance. Ceftriaxone was more common antibiotic causing AAD followed by amoxicillin and amoxicillin plus clavulanic acid. *Candida spp.* was the major pathogen and we isolated from 58.6 % of patients. *Clostridium difficile* associated diarrhea was seen in 18.6 % of Patients. A Known aerobic pathogen was detected in 18.6 % cases of AAD. No pathogens were detected in 4.3% cases.

Conclusion: *Candida spp.* is the major pathogen in AAD in our tertiary care center. However *Clostridium difficile* seems to be an emerging pathogen in our health care setting. It has been reported from the developed countries in epidemic proportions but seems to be just gaining foothold in the Indian scenario. Apart from stoppage of antibiotics, it is important to identify the pathogen in AAD so that appropriate management may be instituted.

Keywords: *Clostridium difficile*, Antibiotic associated diarrhea, *Candida*, Ceftriaxone, Amoxicillin, Proton pump inhibitors, *Clostridium difficile* associated diarrhea

1. INTRODUCTION

Advances in medicine have resulted in increase in the use of antibiotics in health care settings. Indiscriminate use of antibiotics has resulted in the emergence of problems like Antibiotic-associated diarrhea (AAD). 5%–25% patients undergoing antibiotic treatment often develop AAD as a side effect of therapy ranging from a mild illness to a serious complication like pseudomembranous colitis [1]. Almost all the antibiotics have been associated with diarrhea. However some antibiotics are more commonly associated with it e.g Ampicillin, Amoxicillin, Clindamycin and Cephalosporins [2]. Apart from antibiotic use other risk factors such as use of proton pump inhibitors (PPI) and immunosuppressive agents and chemotherapeutic agents can also give rise to a similar presentation [3].

Exposure of the colonic ecosystem to antimicrobial agents results in a shift in population of the microbes as a result of suppression or elimination of some microorganisms or overgrowth by microorganisms not susceptible to these agents, and establishment of antimicrobial-resistant members that are normally are excluded. The normal flora is replaced by pathogenic organisms like *Clostridium difficile*, *Clostridium perfringes*, *Staphylococcus aureus*, *Klebsiella pneumonia*, *Klebsiella oxytoca*, *Pseudomonas spp.* *salmonella spp.*, *Candida spp.*etc which play an important role as an etiological agent of AAD [4].

C.difficile has resulted in nationwide outbreak in the developed world in health care settings. Over the last decade there has been a marked increase in *C.difficile* infection (CDI) incidence and mortality across the United States, Canada, and Europe [3, 4]. However reports of this pathogen from India are limited.

So a prospective cross sectional study was planned to identify the microorganisms associated with AAD with the following Aims & objective-

- 1) To evaluate the role of various antimicrobials and PPI in causation of AAD.
- 2) To determine the prevalence of *Clostridium difficile* in AAD in a tertiary care center.
- 3) To study the role of aerobes and fungus in causation of AAD.

2. MATERIAL AND METHODS

2.1 STUDY DESIGN

A prospective observational study was conducted after ethical approval. 70 patients were enrolled in the study after taking informed consent.

2.1.1 Inclusion criteria: Patients were identified as having AAD if they develop diarrhea in 3 or more days on antibiotic usage and within 4weeks after discontinuation of antibiotic and with no other identifiable cause of diarrhea.

2.1.2 Exclusion criteria- Patients presenting to the hospital with diarrhea without history of antibiotic therapy

2.2 LABORATORY PROCESSING OF THE STOOL SAMPLES

2.2.1 Collection of sample

Stool samples were collected from the patients giving history suggestive of 'antibiotic associated diarrhea'. Samples were collected in sterile wide mouth leak proof tightly lidded container. For anaerobic bacteriology 5 loops full of the sample were immediately transferred to RCM. The stool specimens were processed immediately without any delay.

2.2.2 Macroscopy and Microscopic examination :

- Macroscopically the colour, consistency, presence of blood and mucous was noted.
 - For the microscopic examination thin smear of the stool sample was prepared and stained with gram stain. Smear was examined for the presence of polymorph nuclear leukocytes, yeast cells, presence of pseudohyphae, and morphology of bacteria seen were described.
- A saline and iodine wet mount of the fecal sample was examined for the presence of parasites, eggs and cysts. Patients showing parasitic infestation were excluded from the study.

2.2.3 Follow up of sample for aerobes:

Stool sample was inoculated on-MacConkey agar and Blood agar and incubated directly and after enrichment. All plates were incubated at 37⁰ C overnight. Colonies obtained were identified as per standard techniques [5].

2.2.4 Follow up for fungi :

Stool sample was inoculated on Sabourauds dextrose agar which was incubated at 37⁰ C . Growth of creamy white moist colonies was noted. Gram stain was made from these colonies to look for the presence of yeast cells i.e. round or oval cells showing budding with presence or absence of pseudo

hyphae. Further processing and identification of the organisms was done as per standard microbiological techniques [5].

2.2.5 Follow up of stool sample for anaerobes:

Stool sample from RCM after overnight incubation at 37 °C were then inoculated on to

- a) Neomycin blood agar
- b) Kanamycin – vancomycin blood agar
- c) Willis and hobbs medium
- d) Cycloserine Cefoxitin Fructose Egg yolk Agar (CFFA)

All different type of colonies obtained were then tested for aero tolerance. Organisms which did not grow on aero tolerance plate were regarded as anaerobes. Strict anaerobes obtained were identified as per standard protocol [6].

C.difficile was identified by its colony appearance on CCFA (Fig. 1), chartreuse fluorescence (Fig. 2) and biochemicals.




Fig. 1 Growth of *C.difficile* on CCFA. Colonies are large flat to low umbonate, yellow with a ground glass appearance and a slightly filamentous edge. The medium has changed from orange pink to yellow around the colony




Fig. 2 Colonies of *C.difficile* showing yellow green or chartreuse fluorescence when exposed to ultraviolet light (360nm)

MIC for metronidazole and vancomycin was detected for all *C.difficile* isolate by using the E test method (Himedia).

The gram stain appearance of the stool samples, culture results and clinical presentation of patients were all taken into consideration before deciding the causative organism of antibiotic associated diarrhea

2.2.6 Toxin detection by ELISA

All stool samples were processed for the presence of *C.difficile* toxin A and B by Enzyme immunoassay which was performed by a using commercial kit (Premier Toxins A & B .in vitro Diagnostic Medical Device, USA).The assay was performed according to the manufacturer's instructions.

A positive result was taken to be a test positive for presence of *C.difficile* toxin A and /or B

2.2.7 PCR

Since *C.difficile* is difficult to grow an attempt was also made to detect *C.difficile* in stool by PCR. DNA extraction was done by silica gel method [7, 8]. PCR was performed for detection of species specific regions of the 16S rDNA of *C. difficile* on all stool samples [9]. PCR products were analyzed by electrophoresis using 2% agarose gel. The amplified product was visualized on an UV trans-illuminator. Appearance of expected size band of 157bp for *C.difficile* was noted as PCR positive as shown in Fig. 3.

3. RESULTS

The study was carried on 70 patients developing diarrhea after antibiotic use .Majority of the patients were from the age group 31 to 40 years (24.3%) with a mean age group of 36.9 years. A female preponderance (60%) was seen in the present study. Out patients as well as admitted patients were included in the study. Distribution of patients by hospital department/ services is shown in Table 1.

Table1. Shows distribution of patients by hospital department/ services

Department	No. of patients	Percentage (%)
In patients		
1)Surgery	22	31.4
2)Medicine	19	27.1
3)Obstetrics and Gynecology	14	20
4)Pediatrics	10	14.3
Total	65	92.9
Out patients	5	7.1
Total	70	100

AAD was more common in indoor patients (92.9 %) as compared to outdoor (7.1 %). Majority of patients in present study (31.4%) were from Faculty of Surgery followed by Medicine.

135 The antibiotics which resulted in causation of AAD are shown in Table 2.

136 **Table 2: Shows distribution of antibiotic intake in the study group**

No.	Antibiotic	No.	of	Percentage (%)
			patients	
1	Ceftriaxone	39		55.7
2	Amoxicillin	31		44.3
3	Amoxicillin + clavulanate potassium	29		41.4
4	Amikacin	22		31.4
5	Metronidazole	14		20
6	Norfloxacin	9		12.9
7	Ciprofloxacin	6		8.6
8	Teimethoprim-Sulfomethoxazole	3		4.3
9	Erythromycin	2		2.9
10	Penicillin	1		1.4

137 Patients receiving ceftriaxone more commonly developed AAD, followed by amoxicillin and amoxicillin
 138 plus clavulanic potassium. 47.1% of the patient received multiple antibiotics and 4 (5.7%) patients in
 139 addition received proton pump inhibitors. However, no patient in the current study was receiving only PPI.
 140
 141

142 The predominant organisms isolated from stool in patients of AAD are shown in table no. 3.
 143
 144

145 **Table 3. Shows Predominant organism associated with AAD**

Organism	Total	Percentage (%)
<i>Candida Spp.</i>	41	58.6
• <i>Candida albicans</i>	31	44.3
• <i>Candida non albicans</i>	10	14.3
<i>C.difficile</i> (Culture/PCR/Toxin)	13	18.6
Aerobic organisms	13	18.6

• <i>Klebsiella pneumonia</i>	6	8.6
• <i>Pseudomonas aeruginosa</i>	4	5.7
• <i>Klebsiella oxytoca</i>	1	1.4
• <i>S.aureus</i>	2	2.9
Anaerobic organism	2	2.9
No known pathogen	3	4.3

Candida spp. was the major pathogen isolated from 58.6 % cases of AAD. *Candida albicans* in 44.3 % and *non albicans Candida* in 14.3 % of AAD cases.

Known aerobic pathogen of AAD were isolated from 18.6 % of the patients .Among these *Klebsiella pneumonia* was the predominate isolate in 8.6 % of patients followed by *Pseudomonas aeruginosa* (5.7 %), *Staphylococcus aureus* (2.9%) and *Klebsiella oxytoca* in 1.4 % (Table 3).

In two patients pure growth of *S.aureus* was isolated which comprised 2.9% of the cases of AAD. 4.3% cases did not show any known pathogen of AAD.

Overall 13 (18.6%) patients gave evidence of *C.difficile* infection either by culture, PCR or toxin detection (Table 3). *C.difficile* was isolated from two (2.9 %) patient (Table 4).

Table 4. Demonstration of *C.difficile* in stool (Culture, Toxin and PCR)

N= 70 patients

Test	Total	Percentage (%)
Culture positive	2	2.9
Toxin positive	10	14.3
PCR positive	9	12.9

No other anaerobe apart from *C.difficile* was isolated from the stool samples.

E test showed MIC of 0.19 (ug/ml) and 0.064 (ug/ml) for vancomycin in the two isolates respectively. MIC for metronidazole was 256(ug/ml) and 128 (ug/ml) for the two isolates respectively. Both the isolate were resistant to metronidazole.

9 (12.9%) patient's stool sample showed presence of *C.difficile* DNA by PCR (Fig.3).




Fig. 3 Bacterial PCR for *C.difficile*. 2 percent agarose gel electrophoresis of conventional PCR Product (~ 157 bp) for *C.difficile*. Lane M: Molecular weight marker (1kbp ladder). Lanes 1 to 9 shows positive band for *C.difficile* in stool sample of AAD cases.

So additionally by PCR *C.difficile* could be detected in 7 patient which were not picked up by culture .10 (14.3%) were positive for *C.difficile* toxin. Both the culture positive sample showed presence of *C.difficile* DNA in stool. Three patients who showed *C.difficile* DNA in stool sample did not show presence of *C.difficile* toxin in the sample.

In the present study the only complication encountered was Pseudomembranous colitis in one (7.7%) patient of *Clostridium difficile* associated diarrhea (CDAD).

4. DISCUSSION

Antibiotic usage is a common cause of diarrhea in health care centers. It is a growing nosocomial and public health problem. The prevalence of *C. difficile*-associated disease is global and the incidence varies considerably from place to place.

In present study the maximum number of AAD cases (24.3 %) occurred in the age group of 31 to 40 years .Mean age of the patients was 36.9. Our results are in agreement with Swartzberg et al [10] who also observed that antibiotic associated diarrhea occurred nearly twice as often in patients over twenty years than in younger patients and the mean age observed was 35.7. Some authors have reported AAD to be more common in older age like Gurwith et al [11] and Leigh and Simmons [12] .There was female (60%) preponderance seen in the present study. Swartzberg et al [10] and Wistrom et al [13] also reported AAD cases more common in females. However there have been studies which have reported male predominance [3, 14, 15]. Chaudhry et al. [16] in their study reported that there was no gender predilection.

Maximum patients (92.84%) in the current study were indoor patients as compared to outdoor patients. Various other studies [15, 17, 18, 19, 20] have also reported AAD to be more in hospitalized patients. The reason for this is long term exposure to antibiotics of these patients. Among the hospitalized patients in the current study majority of them belonged to Surgical units (31.4%) followed by medical (27.1%), obstetrics and gynecology (20%) and pediatric units (14.28%) Gerding et al [20] also observed that 75 % of patients in their study belonged to surgical services. However Vishwanath et al. [21] have reported that most of their patients (72%) with AAD were from general medical wards, followed by oncology (12%); surgery (8%), and pediatric wards (8%).

Ward wise prevalence of AAD may differ from center to center based on antibiotic prescribing practices. Incidence of antibiotic associated diarrhea is probably seen more in surgical units because of long term antibiotic treatment are used as a part of surgical prophylaxis after major contaminated or clean contaminated surgery.

In the present study, patients developing AAD had received ceftriaxone (55.7%) more commonly followed by amoxicillin and amoxicillin plus clavulanate potassium. High rates of diarrhea with these drugs probably reflect their common use in our hospital. Other studies have also reported use of cephalosporin to be commonly associated with AAD [10, 18, 19]. All the cases of *C.difficile* associated diarrhea were on ceftriaxone alone or in combination. Among other cephalosporin Gogate et al. [15] reported that cefotaxime in combination with amikacin were responsible for 8.4 % cases and cefotaxime and ampicillin in 7.2% and only cefotaxime in (3.2%).

The other two antibiotics more commonly associated with AAD in the present study were amoxicillin (44.3%) and amoxicillin plus clavulanate potassium (41.4%). Turck et al [22] have shown that the incidence of AAD cases in their study was particularly high after administration of amoxicillin /clavulanate (23%). In the present study among the quinolones norfloxacin was associated with 12.9 % cases and ciprofloxacin with 8.6 % of the cases. Vaishnavi et al.[23] reported that quinolones including fluoroquinolones were associated with AAD in 14.2% of their patients

PPI as a risk factor have been implicated in the causation of *C.difficile* diarrhea because the survival of spores is facilitated by elevated gastric pH levels and due to the effect of PPI on the toxin production of the organism or on immune function of the host. In the present study 4 (30.7%) patients diagnosed as *C.difficile* associated diarrhea were on proton pump inhibitor. Kaneria and Paul [14] reported that all the patients with *C.difficile* associated diarrhea in their study were on PPI. However McFarland et al. [24] in 2007 reported no association between PPI use and nosocomial CDAD .As conflicting data exist and till further evidence is available PPI should be used cautiously.

In the present study *Candida* spp. was the major pathogen and only fungus to be isolated in patients of AAD. These accounted for 58.6 % of AAD cases *C.albicans* was isolated from 44.3% and *Non albicans Candida* from 14.3 % of patients. In a study carried out by Nkwo-Akenji TK et al. [25] .*C. albicans* was identified in 35.9% of samples. A study done by Brad et al. [26] found that *Candida albicans* was responsible for 20% of AAD cases. Vaishnavi et al. [27] have observed that the predominant isolates were *C. tropicalis* followed by *C. albicans* and *C. krusei*. Hyun Joo Song, et al. [28] isolated *Candida albicans* in 5.2% and *Candida tropicalis* in 2.6% AAD cases. The results of the present study suggest that *C. albicans* is an important cause of antibiotic associated diarrhea in our settings. Thus, this fungus should be routinely checked in individuals presenting with diarrhea in patients on prolonged or frequent antibiotic therapy.

18.6 % of known aerobic pathogen was associated with AAD. Among these *Klebsiella pneumonia* was isolated in 8.6 % of patients followed by *Pseudomonas aeruginosa* (5.7 %), *Staphylococcus aureus* (2.9%) and *Klebsiella oxytoca* in 1.4 % Leigh and Simmons [12] observed increased counts of Enterobacteriaceae in 64% of their patients with antibiotic associated diarrhea. A study carried out by Hyun Joo Song et al. [28] reported that *K. pneumoniae* accounted for 15.8% cases of AAD.

Antibiotic-associated-hemorrhagic-colitis (AAHC) is a distinct form of antibiotic-associated-colitis (AAC) caused by *K. oxytoca* .In our study *K. oxytoca* was isolated from 1 (1.4 %) patient .Högenauer et al. [29] in their study have reported that 83.3% patients suffering AAHC tested positive for *K. oxytoca* .A prospective study of hospitalized patients with AAD identified cytotoxic *K. oxytoca* in 16.7% patients with bloody diarrhea [30].

Pseudomonas is also a known nosocomial pathogen. In present study it was isolated from 5.7% of cases. Brad et al. [26] isolated *Pseudomonas aeruginosa* in 72.7% of AAD cases. Kim, Peck, Jung, et al. [31] isolated *P. aeruginosa* from stool cultures of seven patients who developed diarrhea after the administration of antibiotics. Chandra et al. [32] observed *Pseudomonas aeruginosa* in 3 % cases of hospital-acquired diarrhea.

Staphylococcus aureus is known to cause antibiotic associated diarrhea and colitis. In the present study *Staphylococcus aureus* was isolated from 2.9 % of the cases. Various studies have also reported cases

of *S.aureus* associated with antibiotic- associated diarrhea [28,33 ,34 ,35 ,36]. In fact in two patients it was obtained in pure culture in our patients where no other pathogen was detected.

***Clostridium difficile* associated diarrhea**

C. difficile is considered as the most frequent etiological agent of nosocomial diarrhea occurring in hospitalized patients in developed countries, spreads easily to the environment, to the hands of health care workers and subsequently to other patients.

Clostridium difficile was associated AAD in 18.6 % of cases in the present study in the present study. Toxin was demonstrated in 10 (14.9%) patients and PCR demonstrated presence of organism in additional 3 patients.

Prevalence *C.difficile* associated diarrhea varies from 7.3 % to 17.5 % according to different geographical areas [3,14,15,16,21,37,38,39]. The prevalence of *C.difficile* associated diarrhea in present study is almost similar to study conducted by Gogate et al.[15] from Mumbai . However some authors like Chaudhry et al.[16] (7.1 %) and Bhattacharya et al. [37] (7.3%) have shown lower prevalence of *C.difficile* associated diarrhea from New Delhi and Kolkata respectively. Manabe et al [40] from Baltimore,USA reported positivity rate of 14.55 % whereas a higher prevalence rate was reported by Wistron el al.[13] from Sweden. He observed 62.5 % positivity rate of *C.difficile* infection among AAD patients.

In the present study the only complication we encountered was Pseudomembranous colitis (PMC) in one patient (7.7%).Various studies have suggested PMC is the most severe manifestation of CDAD [2,4]. Gurwith et al [11] reported PMC in 2.1% cases of clindamycin associated diarrhea and 0.3% in ampicillin associated diarrhea. However Ingle et al [3] have observed no complications in their study group.

Drug of choice for *C.difficile* infection is metronidazole and vancomycin. Both the isolate were resistant to metronidazole and sensitive to vancomycin. In a study carried out by Nils Henning Zaiß et al [41].All isolates were susceptible to metronidazole and vancomycin by E test method. So metronidazole resistance in *C.difficile* seems to be an emerging phenomenon, though resistance to metronidazole has been reported in other anaerobes [42].

In 4.3% cases no known pathogen was isolated .The cause of AAD in these patient could be due to other mechanisms which include decreased metabolism of carbohydrates, reduced break down of primary bile acids, antibiotic having allergic or toxic effects on intestinal mucosa and their effect on gut motility or increase in the amount of un-degraded fiber in the feces, which increases the bulk of the feces leading to diarrhea [2].

5. CONCLUSION

Thus to conclude *Clostridium difficile* is an emerging pathogen in AAD in health care settings. It has been reported from the developed countries in epidemic proportions but seems to be just gaining foothold in the Indian scenario. However *Candida spp.* remain the major pathogen in AAD. It is important to identify the pathogen in AAD so that appropriate management may be instituted. However restricting the use of antibiotics would go a long way in preventing antibiotic associated diarrhea.

CONSENT

All authors declare that written informed consent was obtained from the patient.

ETHICAL APPROVAL

Ethical clearance was obtained from the institutional ethics committee with reference no. BJMC/IEC/Pharmac/D-1113131-131

REFERENCES

1. Walk ST, Young VB. Emerging Insights into Antibiotic-Associated Diarrhea and *Clostridium difficile* Infection through the Lens of Microbial Ecology. *Interdiscip Perspect Infect Dis*.2008; 2008:125081.
2. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea.*Clin Infect Dis*. 1998 Oct; 27 (4):702-10.
3. Ingle M, Deshmukh A , Desai D , Abraham P , Joshi A , Rodrigues C , Mankeshwar R. Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis. *Indian J Gastroenterol*. 2011, March–April; 30(2):89–93.
4. Ayyagari A, Agarwal J, GargA.Antibiotic associated diarrhoea: infectious causes. *Indian J Med Microbiol*. 2003 Jan-Mar; 21(1):6-11.
5. Koneman EW, Allen SD, Janda WN, Schreckenberger PC, Winn WC. Colour atlas and textbook of Dignostic Microbiology.6th ed. Philadelphia: Lippincott; 2006.
6. Summanene P, Baron EJ, Citron DM, Strong C, Wexler HM, Finegold SM. Wadsworth anerobic Bacteriology Manual.5th ed. California : Star publishing company ; 1993.
7. Boom, R., C. J. A. Sol, M. M. M. Salimans, C. L. Jansen, Wertheim-van Dillen and J van der N. Rapid and simple methods for purification of nucleic acids. *J ClinMicrobiol*. 1990; 28(3):495–503.
8. Carter MJ and IDM. An inexpensive and simple method for DNA purifications on silica particles.. *Nucleic Acids Res*. 1993; 21(4):1044.
9. Balamurugan R, Balaji V, Ramakrishna BS. Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction. *Indian J Med Res*. 2008 May; 127(5):472-7.
10. Swartzberg JE, Maresca RM, Remington JS. Gastrointestinal side effects associated with clinidamycin. 1,000 consecutive patients. *Arch Intern Med*. 1976 Aug; 136(8):876-9.
11. Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. *J Infect Dis*. 1977 Mar;135 Suppl:S104-10
12. Leigh DA, Simmons K.Effect of clindamycin and lincomycin therapy on faecal flora.*JClinPathol*. 1978 May;31(5):439-43.
13. Wiström J, Norrby SR, Myhre EB, Eriksson S,Granström G, Lagergren L, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic treated hospitalized patients: a prospective study. *J Antimicrob Chemother*. 2001 Jan; 47(1):43-50.
14. Kaneria MV, Paul S. Incidence of Clostridium difficile associated diarrhoea in a tertiary care hospital. *J Assoc Physicians India*. 2012 Nov; 60:26-8.
15. Gogate A, De A, Nanivadekar R, Mathur M, Saraswathi K, Jog A, Kulkarni MV. Diagnostic role of stool culture & toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. *Indian J Med Res*. 2005 Dec; 122(6):518-24.
16. Chaudhry R, Joshy L, Kumar L, DhawanB.Changing pattern of Clostridium difficile associated diarrhoea in a tertiary care hospital: A 5 year retrospective study. *Indian J Med Res*. 2008 Apr;127(4):377-82.
17. Lusk RH, Fekety FR Jr, Silva J Jr, Bodendorfer T, Devine BJ, Kawanishi H, Korff L, Nakauchi D, Rogers S, Siskin SB. Gastrointestinal side effects of clindamycin and ampicillin therapy. *J Infect Dis*. 1977 Mar; 135 Suppl: S111-9.
18. Neu HC, Prince A, Neu CO, Garvey GJ. Incidence of diarrhea and colitis associated with clindamycin therapy. *J Infect Dis*. 1977 Mar; 135 Suppl:S120-5.

19. Biddle WL, Harms JL, Greenberger NJ, Miner PB Jr. Evaluation of antibiotic-associated diarrhea with a latex agglutination test and cell culture cytotoxicity assay for *Clostridium difficile*. *Am J Gastroenterol*. 1989 Apr; 84(4):379-82.
20. Gerding DN, Olson MM, Peterson LR, Teasley DG, Gebhard RL, Schwartz ML, Lee JT Jr. *Clostridium difficile*-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. *Arch Intern Med*. 1986 Jan; 146(1):95-100.
21. Vishwanath S, Singhal A, D'Souza A, Mukhopadhyay C, Varma M, Bairy I. *Clostridium difficile* infection at a tertiary care hospital in south India. *J Assoc Physicians India*. 2013 Nov; 61(11):804-6.
22. Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O, Lacombe A, Rembert F, Toursel F, Bernasconi P, Gottrand F, McFarland LV, Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. *J Pediatr Gastroenterol Nutr*. 2003 Jul; 37(1):22-6.
23. Vaishnavi C. Clinical spectrum & pathogenesis of *Clostridium difficile* associated diseases. *Indian J Med Res*. 2010 Apr; 131:487-99.
24. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for *Clostridium difficile*-associated disease within a Veterans Administration health care system. *Clin Infect Dis*. 2007 Nov 1; 45(9):1141-51.
25. Nkuo-Akenji TK, Ndip RN, Ntoko FA. The prevalence of *Candida albicans*-associated diarrhoea in Buea, South West Cameroon. *Afr J Health Sci*. 2002 Jul-Dec; 9(3-4):153-7.
26. Brad GF, Sabau L, Simedrea L, Belei O, Marcovici T, Popoiu C. *Pseudomonas aeruginosa* And Antibiotic-associated Diarrhea In Children. *Timisoara Med J*. 2011; 61(1 – 2): 37-42.
27. Vaishnavi C, Kaur S, Prakash S. Speciation of fecal *Candida* isolates in antibiotic-associated diarrhea in non-HIV patients. *Jpn J Infect Dis*. 2008 Jan; 61(1):1-4.
28. Song HJ, Shim KN, Jung SA, Choi HJ, Lee MA, Ryu KH, Kim SE, Yoo K. Antibiotic-Associated Diarrhea: Candidate Organisms other than *Clostridium Difficile*. *Korean J Intern Med*. 2008 Mar; 23(1):9-15.
29. Högenauer C, Langner C, Beubler E, Lippe IT, Schicho R, Gorkiewicz G, Krause R, Gerstgrasser N, Krejs GJ, Hinterleitner TA. *Klebsiella oxytoca* as a causative organism of antibiotic-associated hemorrhagic colitis. *N Engl J Med*. 2006 Dec 7; 355(23):2418-26.
30. Zollner-Schwetz I, Högenauer C, Joainig M, Weberhofer P, Gorkiewicz G, Valentin T, Hinterleitner TA, Krause R. Role of *Klebsiella oxytoca* in Antibiotic-Associated Diarrhea. *Clin Infect Dis*. 2008 Nov 1; 47(9):e74-8.
31. Kim SW, Peck KR, Jung SI, Kim YS, Kim S, Lee NY, Song JH. *Pseudomonas aeruginosa* as a Potential Cause of Antibiotic-Associated Diarrhea. *J Korean Med Sci*. 2001 Dec; 16(6):742-4.
32. Chandra BK, Singh G, Taneja N, Pahil S, Singhi S, Sharma M. Diarrhoeagenic *Escherichia coli* as a predominant cause of paediatric nosocomial diarrhoea in India. *J Med Microbiol*. 2012 Jun; 61(Pt 6):830-6.
33. Gravet A, Rondeau M, Harf-Monteil C, Grunenberger F, Monteil H, Scheftel JM, Prévost G.. Predominant *Staphylococcus aureus* Isolated from Antibiotic- Associated Diarrhea Is Clinically Relevant and Produces Enterotoxin A and the Bicomponent Toxin LukE-LukD. *J Clin Microbiol*. 1999 Dec; 37(12):4012-9.
34. Altemeier WA, Hummel RP, Hill EO. Staphylococcal Enterocolitis Following Antibiotic Therapy. *Ann Surg*. 1963 Jun; 157(6): 847–857.
35. Kappas A, Shinagawa N, Arabi Y, Thompson H, Burdon D, Dimock F, George RH, Alexander-Williams J, Keighley MR. Diagnosis of pseudomembranous colitis. *Br Med J*. 1978 Mar 18; 1(6114):675-8.
36. Boyce JM, Havill NL. Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillin-resistant *Staphylococcus aureus*. *Am J Gastroenterol*. 2005 Aug; 100(8):1828-34.
37. Bhattacharya MK, Niyogi SK, Rasaily R, Bhattacharya SK, Dutta P, Nag A, Pal SC. Clinical manifestation of *Clostridium difficile* enteritis in Calcutta. *J Assoc Physicians India*. 1991 Sep; 39(9):683-4.

- 419 38. Niyogi SK, Dutta P, Dutta D, Mitra U, Sikdar S. Clostridium difficile and its cytotoxin in
420 hospitalized children with acute diarrhea. Indian Pediatr. 1991 Oct;28(10):1129-32.
- 421 39. Vaishnavi C, Singh M, Kapoor P, Kochhar R. Clinical and demographic profile of patients
422 reporting for Clostridium difficile infection in a tertiary care hospital. Indian J Med
423 Microbiol. 2015 Apr-Jun;33(2):326-7.
- 424 40. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG. Clostridium difficile colitis:
425 an efficient clinical approach to diagnosis. Ann Intern Med. 1995 Dec 1; 123(11):835-40
- 426 41. Zaiß NH, Witte W, Nübel U. Fluoroquinolone Resistance and Clostridium difficile, Germany
427 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 4, April 2010.
- 428 42. Bharadwaj R. Anaerobic microbiology: time to rejuvenate. Indian J Med Microbiol. 2012 Jan-
429 Mar;30(1):3-5